Vitthal Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.45 M
as on 11-12-2024
- Paid Up Capital ₹ 1.45 M
as on 11-12-2024
- Company Age 41 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.90 M
as on 11-12-2024
- Satisfied Charges ₹ 4.00 M
as on 11-12-2024
- Revenue 3.95%
(FY 2022)
- Profit -11.67%
(FY 2022)
- Ebitda -166.71%
(FY 2022)
- Net Worth 3.00%
(FY 2022)
- Total Assets -0.32%
(FY 2022)
About Vitthal Drugs
The Company is engaged in the Transport And Logistics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.45 M and a paid-up capital of Rs 1.45 M.
The company currently has active open charges totaling ₹0.90 M. The company has closed loans amounting to ₹4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Kadambari Bhalotia and Vidyut Bhalotia serve as directors at the Company.
- CIN/LLPIN
U74899DL1983PTC016771
- Company No.
016771
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 1983
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vitthal Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kadambari Bhalotia  | Director | 10-Oct-2017 | Current |
| Vidyut Bhalotia | Director | 20-Dec-2018 | Current |
Financial Performance of Vitthal Drugs.
Vitthal Drugs Pvt Ltd, for the financial year ended 2022, experienced modest growth in revenue, with a 3.95% increase. The company also saw a substantial fall in profitability, with a 11.67% decrease in profit. The company's net worth moved up by a moderate rise of 3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vitthal Drugs?
In 2019, Vitthal Drugs had a promoter holding of 99.95% and a public holding of 0.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Malborough Polychem LimitedActive 38 years 1 monthKadambari Bhalotia and Vidyut Bhalotia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Feb 2024 | ₹0.90 M | Open |
Others Creation Date: 06 Jun 2018 | ₹2.50 M | Satisfied |
Oriental Bank Of Commerce Creation Date: 01 Jun 2001 | ₹1.50 M | Satisfied |
How Many Employees Work at Vitthal Drugs?
Unlock and access historical data on people associated with Vitthal Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vitthal Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vitthal Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
